Steven Cohen Xenon Pharmaceuticals Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 383,290 shares of XENE stock, worth $14.8 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

383,290

Previous 482,022 20.48%

Holding current value

$14.8 Million

Previous $18.8 Million 19.75%

% of portfolio

0.04%

Previous 0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $3.57 Million - $4.34 Million	-98,732 Reduced 20.48%	383,290 $15.1 Million
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $7.47 Million - $9.02 Million	206,163 Added 74.73%	482,022 $18.8 Million
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $25.6 Million - $30 Million	-599,206 Reduced 68.48%	275,859 $11.9 Million
Q4 2023 Feb 14, 2024	SELL	$28.7 - $46.46 $7.19 Million - $11.6 Million	-250,643 Reduced 22.27%	875,065 $40.3 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $33.4 Million - $38.8 Million	977,500 Added 659.55%	1,125,708 $38.5 Million
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $12.4 Million - $15.5 Million	-356,416 Reduced 70.63%	148,208 $5.71 Million
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $22.5 Million - $27.2 Million	-673,700 Reduced 57.17%	504,624 $18.1 Million
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $15.3 Million - $18.2 Million	-461,748 Reduced 28.15%	1,178,324 $46.5 Million
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $22.7 Million - $29.4 Million	738,566 Added 81.93%	1,640,072 $59.2 Million
Q2 2022 Aug 15, 2022	SELL	$25.44 - $35.16 $31.7 Million - $43.8 Million	-1,244,944 Reduced 58.0%	901,506 $27.4 Million
Q1 2022 May 16, 2022	SELL	$25.09 - $33.13 $21.2 Million - $28 Million	-846,147 Reduced 28.27%	2,146,450 $65.6 Million
Q4 2021 Feb 14, 2022	BUY	$15.6 - $35.4 $29.9 Million - $67.8 Million	1,914,797 Added 177.66%	2,992,597 $93.5 Million
Q3 2021 Nov 15, 2021	BUY	$14.86 - $19.45 $2.61 Million - $3.41 Million	175,500 Added 19.45%	1,077,800 $16.5 Million
Q2 2021 Aug 16, 2021	BUY	$16.81 - $20.0 $2.38 Million - $2.83 Million	141,299 Added 18.57%	902,300 $16.8 Million
Q1 2021 May 17, 2021	BUY	$13.65 - $21.31 $3.93 Million - $6.14 Million	288,022 Added 60.9%	761,001 $13.6 Million
Q4 2020 Feb 16, 2021	BUY	$9.49 - $16.04 $245,961 - $415,724	25,918 Added 5.8%	472,979 $7.27 Million
Q3 2020 Nov 16, 2020	SELL	$10.82 - $13.35 $2.3 Million - $2.83 Million	-212,343 Reduced 32.2%	447,061 $4.95 Million
Q2 2020 Aug 14, 2020	BUY	$10.21 - $14.9 $759,123 - $1.11 Million	74,351 Added 12.71%	659,404 $8.27 Million
Q1 2020 May 15, 2020	SELL	$8.08 - $17.57 $2.19 Million - $4.76 Million	-270,747 Reduced 31.64%	585,053 $6.64 Million
Q4 2019 Feb 14, 2020	SELL	$8.11 - $14.65 $561,212 - $1.01 Million	-69,200 Reduced 7.48%	855,800 $11.2 Million
Q2 2019 Aug 14, 2019	BUY	$8.51 - $10.75 $638,250 - $806,250	75,000 Added 8.82%	925,000 $9.12 Million
Q1 2019 May 15, 2019	BUY	$6.39 - $10.42 $798,750 - $1.3 Million	125,000 Added 17.24%	850,000 $8.64 Million
Q4 2018 Feb 14, 2019	BUY	$5.61 - $12.62 $1.82 Million - $4.1 Million	325,000 Added 81.25%	725,000 $4.58 Million
Q3 2018 Nov 14, 2018	BUY	$9.0 - $14.9 $2.9 Million - $4.8 Million	321,900 Added 412.16%	400,000 $5.28 Million
Q2 2018 Aug 14, 2018	SELL	$4.8 - $9.2 $1.1 Million - $2.11 Million	-228,979 Reduced 74.57%	78,100 $719,000
Q1 2018 May 15, 2018	SELL	$2.7 - $4.9 $8,370 - $15,190	-3,100 Reduced 1.0%	307,079 $1.51 Million
Q3 2017 Nov 14, 2017	BUY	$2.45 - $3.25 $759,938 - $1.01 Million	310,179	310,179 $915,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.41B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account